1-2 of 2
Virginia K. Langmuir
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Glen J. Weiss, Jeffrey R. Infante, E. Gabriela Chiorean, Mitesh J. Borad, Johanna C. Bendell, Julian R. Molina, Raoul Tibes, Ramesh K. Ramanathan, Karen Lewandowski, Suzanne F. Jones, Mario E. Lacouture, Virginia K. Langmuir, Hank Lee, Stew Kroll, Howard A. Burris, III
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (9): 2997–3004.
https://doi.org/10.1158/1078-0432.CCR-10-3425
Published: 01 May 2011
View article titled, Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
Open the PDF for Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies in another window
Includes: Supplementary data
Journal Articles

Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer

Adrian M. Jubb, Kathy D. Miller, Hope S. Rugo, Adrian L. Harris, Dafeng Chen, James D. Reimann, Melody A. Cobleigh, Maike Schmidt, Virginia K. Langmuir, Kenneth J. Hillan, Daniel S. Chen, Hartmut Koeppen
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (2): 372–381.
https://doi.org/10.1158/1078-0432.CCR-10-1791
Published: 16 January 2011
View article titled, Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer
Open the PDF for Impact of Exploratory Biomarkers on the Treatment Effect of Bevacizumab in Metastatic Breast Cancer in another window
Includes: Supplementary data